Zoetis Inc.
- Jurisdiction
United States - LEI
549300HD9Q1LOC9KLJ48 - ISIN
US98978V1035 (ZTS )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€96.54 27.5% overvalued - Financial strength (Piotroski F-Value)
-
8
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
7
/ 7
Profile
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€8.00B - Gross margin
70.7% - EBIT
€3.00B - EBIT margin
37.5% - Net income
€2.23B - Net margin
27.8%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
- Last dividend amount
-
$0.50 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
32.1%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Gilbert Cisneros | September 12, 2025 | $1.00K–$15.00K |
| Lisa McClain | September 12, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Jefferson Shreve | June 22, 2025 | $15.00K–$50.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Terry Smith |
|
|
|
Buy |
| Ray Dalio |
|
|
|
Buy |
| Nancy Zevenbergen |
|
|
|
Buy |